Literature DB >> 6159172

Somatosensory evoked potentials: abnormalities with focal brain lesions remote from the primary sensorimotor area.

J A Obeso, J F Marti-Masso, N Carrera.   

Abstract

Somatosensory evoked potentials (SEPs) were recorded in 41 patients with focal brain lesions recognized by computerized tomography. 21 patients presented damage of the primary sensorimotor area (PSMA), and their SEPs were reduced in amplitude and increased in latency for the two early components (N-22 and N-39), in accordance with previous evidence. The other 20 patients pesented lesions remote from the PSMA, 15 (71%) showing abnormal SEPs mainly characterized by increment in amplitude and duration of N-22 and N-39. Abnormalities of the N-70 and later waves were not specific for any type of lesion. SEPs appeared more sensitive than the EEG for detecting brain dysfunction. The physiopathological and clinical importance of these findings are discussed.

Entities:  

Mesh:

Year:  1980        PMID: 6159172     DOI: 10.1016/0013-4694(80)90352-1

Source DB:  PubMed          Journal:  Electroencephalogr Clin Neurophysiol        ISSN: 0013-4694


  4 in total

1.  Short- and long-latency tibial somatosensory evoked potentials in cerebral lesions affecting Rolandic leg areas.

Authors:  N S Chu
Journal:  J Neurol       Date:  1987-02       Impact factor: 4.849

2.  Functional prognosis in stroke: use of somatosensory evoked potentials.

Authors:  B D Zeman; C Yiannikas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

3.  The application of evoked potentials in the diagnosis and follow-up of children with intracranial tumors.

Authors:  J J Rotteveel; E J Colon; G Hombergen; G B Stoelinga; R Lippens
Journal:  Childs Nerv Syst       Date:  1985       Impact factor: 1.475

4.  Understanding diaschisis models of attention dysfunction with rTMS.

Authors:  Javier O Garcia; Lorella Battelli; Ela Plow; Zaira Cattaneo; Jean Vettel; Emily D Grossman
Journal:  Sci Rep       Date:  2020-09-10       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.